Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Juanita Madison on Handling the Provenge Process

May 23rd 2011

Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process

Juanita Madison Describes the Provenge Treatment Process

May 20th 2011

Juanita Madison from Seattle Cancer Care Alliance Describes the Provenge Treatment Process

Suzanne Beauchene on the Provenge Treatment Process

May 20th 2011

Suzanne Beauchene from Seattle Cancer Care Alliance Discusses the Provenge Treatment Process from Start to Finish

PSA Found to Be Highly Predictive of Long-Term Risk of Death From Prostate Cancer

May 18th 2011

Prostate-specific antigen (PSA) levels can accurately predict the risk of developing metastasis or death from prostate cancer up to 30 years later

Dr. Markman Discusses the Swedish PSA Screening

May 18th 2011

Dr. Markman Discusses the Swedish PSA Screening

Dr. Pecora on Results from the Swedish PSA Study

May 18th 2011

Dr. Pecora on Results from the Swedish PSA Study

Dr. Markman Discusses the Importance of Screening

May 18th 2011

Dr. Markman Discusses the Importance of Cancer Screening

Dr. Pecora Evaluates the PLCO Study Findings

May 18th 2011

Dr. Pecora Evaluates the Prostate, Lung, Colorectal and Ovarian Cancer Study Findings

Provenge Treatment Requires Multidisciplinary Care Coordination

May 6th 2011

At ONS researchers from the Seattle Cancer Care Alliance (SCCA) discussed their multidisciplinary care coordination approach for treating patients with Provenge

FDA Approves Abiraterone as Prostate Cancer Treatment

April 28th 2011

Abiraterone acetate gains FDA approval by demonstrating the ability to extend survival in patients with metastatic castrate-resistant prostate cancer

Dr. Crawford on Alternatives to Biopsy in Prostate Cancer

April 28th 2011

Dr. Crawford Discusses Alternatives to Biopsy in Prostate Cancer

Half of Men Feel Worse After Prostatectomy

April 25th 2011

The difficulties with choosing a prostate cancer treatment were highlighted once again by a recent study published in the Journal of Urology

Dr. Dreicer on Prostate Cancer Screening Practices

April 24th 2011

Translational Science in Prostate Cancer: Exploring the Synergies Between Basic Research and Clinical Medicine

April 21st 2011

Translational medicine is currently the focus of much attention in the medical and research community and is the wave of the foreseeable future

Dr. Crawford Talks About 3D Mapping Biopsies

April 19th 2011

E. David Crawford, MD from the University of Colorado Health Sciences Center Talks About 3D Mapping Biopsies

Dr. Gomella on Novel Prostate Cancer Immunotherapies

April 18th 2011

Dr. Leonard Gomella from the Jefferson Kimmel Cancer Center on Novel Prostate Cancer Immunotherapies

Dr. Crawford Talks About Robotic Treatment

April 15th 2011

Immunotherapies: Avoiding collisions once the brake is released

April 13th 2011

Immunotherapies again made headlines in oncology last month

Dr. Crawford on Challenges Facing Active Surveillance

April 12th 2011

PSA: To Screen or Not to Screen

April 12th 2011

Screening for prostate cancer does work, despite controversy about its efficacy, according to IPCC Co-chair Leonard G. Gomella